{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:05Z","timestamp":1785542405647,"version":"3.56.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immunoglobulin light chain (AL) amyloidosis is a disorder of clonal plasma cells characterized by deposition of amyloid fibrils in a variety of tissues, leading to end-organ injury. Renal or cardiac involvement is most common, though any organ outside the central nervous system can develop amyloid deposition, and symptomatic presentations may consequently vary. The variability and subtlety of initial clinical presentations may contribute to delayed diagnoses, and organ involvement is often quite advanced and symptomatic by the time a diagnosis is established. Additionally, while organ function can improve with plasma-cell-directed therapy, such improvement lags behind hematologic response. Consequently, highly effective supportive care, including symptom management, is essential to improve quality of life and to maximize both tolerance of therapy and likelihood of survival. Considering the systemic nature of the disease, close collaboration between clinicians is essential for effective management.<\/jats:p>","DOI":"10.3389\/fonc.2022.907584","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T06:00:36Z","timestamp":1655964036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Christopher E.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirnela","family":"Byku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald A.","family":"Hladik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koyal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Traub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic Immunoglobulin Light Chain Amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m116.736736","article-title":"Cell Damage in Light Chain Amyloidosis","volume":"291","author":"Marin-Argany","year":"2016","journal-title":"J Biol Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.75","article-title":"Cytotoxicity of Amyloidogenic Immunoglobulin Light Chains in Cell Culture","volume":"1","author":"Sikkink","year":"2010","journal-title":"Cell Death Dis"},{"key":"B5","first-page":"45","article-title":"Primary Systemic Amyloidosis: Clinical and Laboratory Features in 474 Cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients With AL Amyloidosis: An 8-Year Study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and Natural History of Primary Systemic Amyloidosis in Olmsted County, Minnesota, 1950 Through 1989 [See Comments]","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 Through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL Amyloidosis: A Real-World Study Using Us Claims Data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03215.x","article-title":"Peripheral Nerve Involvement in Primary Systemic AL Amyloidosis: A Clinical and Electrophysiological Study","volume":"18","author":"Matsuda","year":"2011","journal-title":"Eur J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL Amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000506760","article-title":"Supportive Care in AL Amyloidosis","volume":"143","author":"Cibeira","year":"2020","journal-title":"Acta Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00412-8","article-title":"Changes in Patient-Reported Outcomes in Light Chain Amyloidosis in the First Year After Diagnosis and Relationship to Nt-Probnp Change","volume":"11","author":"D\u2019Souza","year":"2021","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570010","article-title":"A Staging System for Renal Outcome and Early Markers of Renal Response to Chemotherapy in AL Amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-Bortezomib-Dexamethasone (Cybord) Produces Rapid and Complete Hematologic Response in Patients With AL Amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.7614","article-title":"New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.08.002","article-title":"Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins","volume":"34","author":"Karam","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.006","article-title":"A Modern Primer on Light Chain Amyloidosis in 592 Patients with Mass Spectrometry\u2013Verified Typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1001\/archinte.1992.00400230061010","article-title":"Dialysis Support of Patients With Primary Systemic Amyloidosis","volume":"152","author":"Gertz","year":"1992","journal-title":"Arch Internal Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dialysis Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1295944","article-title":"A Good Clonal Response to Chemotherapy in AL Amyloidosis Is Associated With Improved Quality of Life and Function at 1 Year","volume":"24","author":"Carter","year":"2017","journal-title":"Amyloid"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.30.5235","article-title":"Outcome in Renal AL Amyloidosis After Chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC CardioOncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive Therapy in the Presence of Proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.12.001","article-title":"A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome","volume":"5","author":"Lin","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) Cardiac Amyloidosis","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.03.029","article-title":"Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/circep.117.005443","article-title":"Cancer Treatment\u2013Induced Arrhythmias","volume":"10","author":"Buza","year":"2017","journal-title":"Circulation: Arrhythmia Electrophysiology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13025","article-title":"Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long Term Outcomes of Cardiac Transplant for Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.05.040","article-title":"Frequencies and Types of Arrhythmias in Patients With Systemic Light-Chain Amyloidosis With Cardiac Involvement Undergoing Stem Cell Transplantation on Telemetry Monitoring","volume":"104","author":"Goldsmith","year":"2009","journal-title":"Am J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic Findings in Primary Systemic Amyloidosis and Biopsy-Proven Cardiac Involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin Use in Systemic Light-Chain (AL) Amyloidosis: Contra-Indicated or Cautious Use","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.10.018","article-title":"Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation","volume":"164","author":"Mentias","year":"2022","journal-title":"Am J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000549","article-title":"2017 Aha\/Acc\/Hrs Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/jaha.120.016038","article-title":"Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients With Amyloid Cardiomyopathy","volume":"9","author":"Higgins","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12123","article-title":"Implantable Cardioverter Defibrillators in Patients With Cardiac Amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaa094","article-title":"Outcomes in Patients With Cardiac Amyloidosis and Implantable Cardioverter-Defibrillator","volume":"22","author":"Kim","year":"2020","journal-title":"EP Europace"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13818","article-title":"Prevalence and Determinants of Iron Deficiency in Cardiac Amyloidosis","volume":"9","author":"Jobb\u00e9-Duval","year":"2022","journal-title":"ESC Heart Failure"},{"key":"B42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron Deficiency in Heart Failure","volume":"7","author":"Von Haehling","year":"2019","journal-title":"JACC: Heart Failure"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32339-4","article-title":"Ferric Carboxymaltose for Iron Deficiency at Discharge After Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/archinte.1989.00390020080016","article-title":"Peripheral Neuropathy as an Early Marker of AL Amyloidosis","volume":"149","author":"Duston","year":"1989","journal-title":"Arch Internal Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000834","article-title":"A Prospective Observational Study of 915 Patients With Systemic AL Amyloidosis Treated With Upfront Bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European Collaborative Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Upfront Treatment of Systemic AL Amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(98)00037-0","article-title":"Prognosis of Patients With Primary Systemic Amyloidosis Who Present With Dominant Neuropathy","volume":"104","author":"Rajkumar","year":"1998","journal-title":"Am J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v77.2.257.257","article-title":"Response Rates and Survival in Primary Systemic Amyloidosis","volume":"77","author":"Gertz","year":"1991","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21483","article-title":"Primary AL Amyloid Polyneuropathy Successfully Treated With High-Dose Melphalan Followed by Autologous Stem Cell Transplantation","volume":"41","author":"Katoh","year":"2010","journal-title":"Muscle Nerve"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d55f4d","article-title":"Stem Cell Transplantation in Patients With Autonomic Neuropathy Due to Primary (AL) Amyloidosis","volume":"74","author":"Dingli","year":"2010","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0511","article-title":"Pharmacologic Interventions for Painful Diabetic Neuropathy: An Umbrella Systematic Review and Comparative Effectiveness Network Meta-Analysis","volume":"161","author":"Griebeler","year":"2014","journal-title":"Ann Intern Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/wnl.0000000000013038","article-title":"Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary","volume":"98","author":"Price","year":"2022","journal-title":"Neurology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000781","article-title":"Orthostatic Hypotension and Drug Therapy in Patients at an Outpatient Comprehensive Geriatric Assessment Unit","volume":"34","author":"Press","year":"2016","journal-title":"J Hypertens"},{"key":"B55","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/archpsyc.1981.01780320095011","article-title":"Cardiovascular Effects of Therapeutic Doses of Tricyclic Antidepressants","volume":"38","author":"Glassman","year":"1981","journal-title":"Arch Gen Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcp074189","article-title":"Neurogenic Orthostatic Hypotension","volume":"358","author":"Freeman","year":"2008","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of Midodrine Vs Placebo in Neurogenic Orthostatic Hypotension","volume":"277","author":"Low","year":"1997","journal-title":"JAMA"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000815","article-title":"Midodrine for Orthostatic Hypotension and Recurrent Reflex Syncope: A Systematic Review","volume":"83","author":"Izcovich","year":"2014","journal-title":"Neurology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018786954","article-title":"Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-Analysis and Mixed Treatment Comparison of Randomized Trials","volume":"52","author":"Chen","year":"2018","journal-title":"Ann Pharmacotherapy"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-016-0349-7","article-title":"Meta-Analysis of the Safety and Efficacy of Droxidopa for Neurogenic Orthostatic Hypotension","volume":"26","author":"Elgebaly","year":"2016","journal-title":"Clin Autonomic Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2021-151573","article-title":"Droxidopa for Treatment of Refractory Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series","volume":"138","author":"Ruiz Lopez","year":"2021","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13256-020-02405-w","article-title":"Droxidopa as an Effective Treatment for Refractory Neurogenic Orthostatic Hypotension and Reflex Bradycardia in Amyloid Light-Chain Amyloidosis: A Case Report","volume":"14","author":"Ho","year":"2020","journal-title":"J Med Case Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of Immunoglobulin Light Chain Amyloidosis","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"B64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archneur.63.4.noc50340","article-title":"Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension","volume":"63","author":"Singer","year":"2006","journal-title":"Arch Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004340","article-title":"Efficacy of Single or Combined Midodrine and Pyridostigmine in Orthostatic Hypotension","volume":"89","author":"Byun","year":"2017","journal-title":"Neurology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/art.22959","article-title":"Soft Tissue, Joint, and Bone Manifestations of AL Amyloidosis: Clinical Presentation, Molecular Features, and Survival","volume":"56","author":"Prokaeva","year":"2007","journal-title":"Arthritis Rheumatism"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-20-01146","article-title":"Orthopaedic Manifestations of Amyloidosis","volume":"29","author":"Zhang","year":"2021","journal-title":"J Am Acad Orthop Surg"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-25304","article-title":"Pulmonary and Tracheobronchial Amyloidosis","volume":"23","author":"Berk","year":"2002","journal-title":"Semin Respir Crit Care Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"170046","DOI":"10.1183\/16000617.0046-2017","article-title":"The Lung in Amyloidosis","volume":"26","author":"Milani","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2442-x","article-title":"Local Vs. Systemic Pulmonary Amyloidosis\u2014Impact on Diagnostics and Clinical Management","volume":"473","author":"Baumgart","year":"2018","journal-title":"Virchows Archiv"},{"key":"B71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab Plus Cybord for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-In Results of Andromeda","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31706","article-title":"Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma","volume":"124","author":"Chari","year":"2018","journal-title":"Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra023144","article-title":"Molecular Mechanisms of Amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(12)60634-x","article-title":"Symptomatic Gastric Amyloidosis in Patients With Primary Systemic Amyloidosis","volume":"68","author":"Menke","year":"1993","journal-title":"Mayo Clin Proc"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.068155","article-title":"Amyloidosis of the Gastrointestinal Tract: A 13-Year, Single-Center, Referral Experience","volume":"98","author":"Cowan","year":"2013","journal-title":"Haematologica"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01669.x","article-title":"Gastrointestinal Manifestations of Amyloidosis","volume":"103","author":"Ebert","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.09.001","article-title":"Liver and Gastrointestinal Involvement","volume":"34","author":"Rosenzweig","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1608705","article-title":"Symptomatic Fluid Drainage: Peritoneovenous Shunt Placement","volume":"34","author":"Yarmohammadi","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/nejmicm1716472","article-title":"Macroglossia in Light-Chain Amyloidosis","volume":"378","author":"Melo Alves","year":"2018","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.08.004","article-title":"Systemic Amyloidosis Caused by Monoclonal Immunoglobulins: Soft Tissue and Vascular Involvement","volume":"34","author":"Hoffman","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000330238","article-title":"Macroglossia Due to Systemic Amyloidosis: Is There a Role for Radiotherapy","volume":"4","author":"Thibault","year":"2011","journal-title":"Case Rep Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"bcr2015214078","DOI":"10.1136\/bcr-2015-214078","article-title":"Surgical Management of Macroglossia Secondary to Amyloidosis","volume":"9","author":"Gadiwalla","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.04.036","article-title":"Rational Management of Macroglossia Due to Acquired Systemic Amyloidosis: Does Surgery Play a Role","volume":"67","author":"Guijarro-Mart\u00ednez","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2011.574354029","article-title":"The Role of Minor Salivary Gland Biopsy in the Diagnosis of Systemic Amyloidosis: Results of a Prospective Study in 62 Patients","author":"Foli","year":"2011","journal-title":"Amyloid"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.07.026","article-title":"Minor Salivary Gland Biopsy Is More Effective Than Normal Appearing Skin Biopsy for Amyloid Detection in Systemic Amyloidosis: A Prospective Monocentric Study","volume":"57","author":"Lecadet","year":"2018","journal-title":"Eur J Intern Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/bf01451299","article-title":"Sicca Syndrome as an Initial Symptom of Amyloidosis","volume":"17","author":"Jardinet","year":"1998","journal-title":"Clin Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1001\/archinte.1983.00350120123027","article-title":"Primary Amyloidosis Presenting as Sj\u00f6gren's Syndrome","volume":"143","author":"Gogel","year":"1983","journal-title":"Arch Internal Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"Eular Recommendations for the Management of Sj\u00f6gren\u2019s Syndrome With Topical and Systemic Therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.06.027","article-title":"Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome","volume":"91","author":"Muchtar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.07.004","article-title":"Amyloid Arthropathy Associated With Multiple Myeloma: A Systematic Analysis of 101 Reported Cases","volume":"43","author":"Elsaman","year":"2013","journal-title":"Semin Arthritis Rheumatism"},{"key":"B91","article-title":"Amyloid Arthropathy in the Course of Multiple Myeloma","volume":"29","author":"Fautrel","year":"2002","journal-title":"J Rheumatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02183.x","article-title":"Bleeding Symptoms and Coagulation Abnormalities in 337 Patients With AL-Amyloidosis","volume":"110","author":"Mumford","year":"2000","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.6.1885","article-title":"Acquired Factor X Deficiency in Patients With Amyloid Light-Chain Amyloidosis: Incidence, Bleeding Manifestations, and Response to High-Dose Chemotherapy","volume":"97","author":"Choufani","year":"2001","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830110414","article-title":"Factor-X Deficiency in Amyloidosis: A Critical Review","volume":"11","author":"Greipp","year":"1981","journal-title":"Am J Hematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","article-title":"Bleeding Manifestations in 100 Patients With Amyloidosis","volume":"249","author":"Yood","year":"1983","journal-title":"JAMA"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and Bleeding: Pathophysiology, Diagnosis, and Therapy","volume":"47","author":"Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12617","article-title":"Prevalence and Predictors of Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis","volume":"281","author":"Muchtar","year":"2017","journal-title":"J Internal Med"},{"key":"B98","first-page":"1","article-title":"NCCN Clinical Practice Guidelines in Oncology: Systemic Light Chain Amyloidosis. Version 1.2022","author":"Kumar","year":"2021","journal-title":"Natl Compr Cancer Network"},{"key":"B99","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/nejmoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.907584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T06:00:41Z","timestamp":1655964041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.907584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":99,"alternative-id":["10.3389\/fonc.2022.907584"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.907584","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"article-number":"907584"}}